4//SEC Filing
Moore Matthew Richard 4
Accession 0001787306-24-000072
CIK 0001787306other
Filed
May 2, 8:00 PM ET
Accepted
May 3, 4:29 PM ET
Size
7.5 KB
Accession
0001787306-24-000072
Insider Transaction Report
Form 4
Moore Matthew Richard
SVP and Chief Business Officer
Transactions
- Award
Common Stock
2024-05-01+4,166→ 150,186 total - Sale
Common Stock
2024-05-02$8.74/sh−4,681$40,902→ 145,505 total
Footnotes (4)
- [F1]Represents Restricted Stock Units ("RSUs"), initial grant on February 22, 2024, that were subject to a performance-based vesting condition, that was determined to be satisfied on the Vesting Commencement Date, May 1, 2024.
- [F2]The RSUs will vest in twelve equal quarterly installments on the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer on each vesting date.
- [F3]Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the RSUs, the shares were sold upon the vesting of the RSUs solely to cover applicable tax withholding.
- [F4]The transaction was executed in multiple trades in prices ranging from $8.47 to $9.07, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Documents
Issuer
Arcutis Biotherapeutics, Inc.
CIK 0001787306
Entity typeother
Related Parties
1- filerCIK 0001840191
Filing Metadata
- Form type
- 4
- Filed
- May 2, 8:00 PM ET
- Accepted
- May 3, 4:29 PM ET
- Size
- 7.5 KB